Virtual Reality in Hemodialysis to Improve Psychological Well-being

Depressive Symptoms Clinical Trial

Official title:

Positive Psychological Intervention Delivered Using Virtual Reality in Hemodialysis Patients With Comorbid Depression: Randomized Controlled Trial Assessing Feasibility and Efficacy Testing

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05642364
• Other study ID #: 19190
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2023
• Est. completion date: July 2024

Study information

• Verified date: December 2022
• Source: University of Illinois at Urbana-Champaign
• Contact: Rosalba Hernandez, PhD
• Phone: 3129965706
• Email: rherna17[@]uic.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The long-term goal is to create behavioral health technologies to advance the science that leverages state-of-the-art technology to delivery psychotherapeutic treatment to individuals on hemodialysis (HD) to improve their emotional well-being, quality of life, and overall health. The objective in this small R01 study is to design a virtual reality (VR) platform, that fully immerses users into a fictitious lifelike environment, to deliver an evidence-based positive psychological intervention and to test whether it improves the emotional well-being of individuals on HD with comorbid depression. In this proposed 2-arm randomized controlled trial, the investigators hypothesize that delivery of psychotherapy in individuals on HD using a VR environment will prove feasible and will result in significant improvements in depressive symptoms, quality of life, and treatment adherence, along with reduced rates of hospitalization when compared to an active control condition-all while serving as a cost-effective and far-reaching platform for expansive dissemination. The Specific Aims are: Aim #1: To develop VR software to immersively deliver the skills taught in a 5-week evidence-based positive psychological intervention in individuals on HD to improve their emotional well-being. Aim #2: To evaluate the acceptability and feasibility of a 5-week positive psychological intervention, delivered using a VR platform through consideration of rates of recruitment, refusal, retention, (non)compliance, and adherence. Aim #3: To test initial efficacy of the VR-based psychotherapeutic intervention, compared to a control arm, on outcomes of depression, psychological well-being, quality of life, treatment adherence, HD sessions missed, and hospitalizations in HD patients. Knowledge gained from completion of the proposed research will result in the first VR software application to deliver psychotherapy to individuals on HD, while simultaneously allowing them to leave the confines of the clinic and virtually travel to distant regions of the world. This new therapeutic approach can be used to successfully address the added burden of psychological distress experienced by individuals on HD, with the potential to positively impact their quality of life, engagement in healthful behaviors, and overall healthy longevity. And, these findings will yield data essential for a fully-powered trial testing important health outcomes and biomarkers in individuals on HD.

Description:

Hemodialysis (HD) is a taxing procedure with extensive illness burden and arduous self-care demands. As such, more than 30% of individuals on HD experience elevated symptoms of depression-and, research shows that comorbid depression is associated with adverse kidney disease outcomes, greater risk of hospitalization, and decreased survival rates. Current interventions to treat depressive symptoms in individuals on HD are resource intensive, infrequently administered, and often involve delivery of psychotherapy by highly-trained clinicians via multiple face-to-face communications. There remains a critical scientific gap for easily disseminatable and efficient strategies to improve emotional well-being profiles of individuals on HD in the U.S. and around the world. The objective in this small R01 study is to design a virtual reality (VR) platform that fully immerses users into a fictitious lifelike environment, to deliver an evidence-based positive psychological intervention and to test whether it improves the emotional well-being of individuals on HD with comorbid depression. For instance, during the module focused on mindfulness/meditation, the investigators will use a head-mounted display to fully immerse and transport individuals on HD to an open field beside a calming stream where they will engage in a 12-minute guided meditation. As such, the investigators propose to conduct a 2-arm randomized controlled trial in which individuals on HD (N=84) will be randomly assigned to receive either the JovialityTM VR-based positive psychological intervention or an active control condition (i.e., 2-dimensional wildlife footage and nature-based settings with inert music). The investigators hypothesize that chairside delivery of psychotherapeutic treatment in individuals on HD using a VR environment will prove feasible and will result in significant improvements in depressive symptoms, quality of life, and treatment adherence, with lower evident rates for missed HD sessions and lower hospitalizations-all while serving as a more cost-effective and far- reaching platform that will greatly expand dissemination. Knowledge gained from completion of the proposed research will result in the first VR software application to deliver psychotherapy to HD patients, while simultaneously allowing them to leave the confines of the clinic and virtually travel to distant regions of the world.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 84
• Est. completion date: July 2024
• Est. primary completion date: October 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• 1) HD patient with at least three months since treatment initiation
• 2) Beck Depression Inventory-II (BDI-II) score =11
• 3) age 21 or older
• 4) visual and audio acuity to immerse in our VR world
• (5) fluent in English or Spanish

Exclusion Criteria:

• 1) unavailable for study period
• 2) prevalent cognitive impairment denoting dementia
• 3) physical limitation restricting use of a head-mounted display
• 4) history of epilepsy, seizures, or vertigo.

Related Conditions & MeSH terms

• Depression
• Depressive Symptoms
• End Stage Kidney Disease
• Kidney Diseases
• Kidney Failure, Chronic

Intervention

Behavioral:
• Joviality(TM)
5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display

Other:
• Inert Virtual Reality
Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
University of Illinois at Urbana-Champaign	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Northwestern University, University of Illinois at Chicago

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility: Recruitment	Proportion of potential enrollees who were approached for recruitment.	Through study completion, an average 6 months.
Primary	Feasibility: Retention rates	Defined as completing all post-intervention assessments, categorized as a binary outcome Target: =75%	Post-intervention at 6-months
Primary	Feasibility: Non-Compliance/Adherence	Measured by the proportion of the intervention completed (e.g., number of virtual reality environments viewed out of the total possible available across skill lessons in the intervention). Target: =75%	Immediately post-intervention at 5-weeks
Primary	Feasibility: Refusal rates	Proportion of potential enrollees who were approached for recruitment but decided not to enroll.	Before enrollment
Primary	Acceptability as assessed by whether a participant would recommend the JovialityTM software	Acceptability as measured by whether a participant would recommend JovialityTM to other HD patients (0 definitely not, to 10 definitely yes). Target: =8.0	Immediately post-intervention at 5-weeks
Secondary	Depressive symptoms	Depressive symptomatology will be assessed using the Beck Depression Inventory-II. Scores range from 1 to 40 where a higher score indicates worse symptoms of depression.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Kidney Disease and Quality of Life	Kidney Disease and Quality of Life (KDQOL-SF™). The scoring procedure first transforms the raw precoded numeric values of items to a 0-100 possible range, with higher transformed scores reflecting better quality of life.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Number of missed hemodialysis treatment sessions	Research staff will extract information from patient medical records to record the number of missed hemodialysis treatment sessions	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Emergency department visits and/or hospitalizations	Research staff will extract information from patient medical records to record the number of emergency department visits and days of hospitalizations.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) computer adaptive test for depressive symptoms	The Patient-Reported Outcomes Measurement Information System (PROMIS) computer adaptive test for depressive symptoms (range values: 28- 140) will serve as an additional measure to triangulate findings of the Beck Depression Inventory-II.; A higher PROMIS T-score represents more of the concept being measured.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) for anxiety	The PROMIS adaptive measures for anxiety (range values: 29-145) will be used. A higher PROMIS T-score represents more of the concept being measured.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) for perceived stress	The PROMIS adaptive measures for perceived stress (range values: 29-145) will be used.; A higher PROMIS T-score represents more of the concept being measured.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) for life satisfaction	The PROMIS adaptive measures for life satisfaction (range values: 10-60) will be used. A higher PROMIS T-score represents more of the concept being measured.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) for positive affect	The PROMIS adaptive measures for positive affect (range values: 34-170) will be used.; A higher PROMIS T-score represents more of the concept being measured.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) for life meaning and purpose	The PROMIS adaptive measures for life meaning and purpose (range values 4-60) will be used. A higher PROMIS T-score represents more of the concept being measured.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS) for self-efficacy for managing emotions in the context of a chronic condition	The PROMIS adaptive measures for self-efficacy for managing emotions in the context of a chronic condition (range values: 25-125) will be used. A higher PROMIS T-score represents more of the concept being measured.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Psychological well-being measured with the 7-item State Optimism Measure	Additional measures of psychological well-being will include the optimism using the 7-item State Optimism Measure. Scoring is mean score of items 1-7 with a higher score indicating greater state optimism.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Psychological well-being measured with the Emotional Vitality Measure	Additional measures of psychological well-being will also include emotional vitality (range values 0-110), as measured using select items of the General Well-being Schedule. There are three proposed cut-points: total scores of 0-60 reflect "severe distress", 61-72 "moderate distress" and 73-110 "positive well-being"	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
Secondary	Psychological well-being measured with the Flourishing Index	The "Flourish" measure is obtained by summing the scores from each of the first five domains. The "Secure Flourish" measure is obtained by summing the scores from all six domains including the financial and material stability domain. Each of the questions is assessed on a scale of 0-10.; The secure flourishing index score is obtained by summing the scores from the twelve questions in all six domains and results in a score from 0 - 120. Often, for purposes of interpretation, the flourishing and secure flourishing scores are reported as averages of the questions (rather than sums) so that all scores are on a scale of 0-10.	Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)